Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Greenlight Capital. This analysis is provided for institutional research purposes only and is not investment advice.
"Greenlight Capital sits out the AI infrastructure boom, warning of a multi-trillion dollar mathematical mismatch, while finding selective value in PG&E and clinical biotech."
Greenlight Capital returned -3.6% net in Q3 2025, lagging the S&P 500's 8.1% gain. The fund dedicates a significant portion of the letter to debunking the financial logic of the current AI investment cycle. They argue that projected global AI capital expenditures ($6.7 trillion through 2030) are completely out of line with addressable revenues, requiring AI businesses to capture 100% of today's global ad and subscription markets to break even. They describe how the AI supply chain artificially inflates revenue numbers through circular spending among loss-making players. In portfolio activity, Greenlight established a medium-sized position in Pacific Gas & Electric (PCG) on the basis of positive regulatory reforms, highlighted their micro-cap position in Coya Therapeutics (COYA), and exited a highly successful five-year investment in Teck Resources (TECK) with a 52% net IRR.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Greenlight Capital sits out the AI infrastructure boom, warning of a multi-trillion dollar mathematical mismatch, while finding selective value in PG&E and clinical biotech....
Growth Outlook
Market outlook remains low conviction: Greenlight Capital sits out the AI infrastructure boom, warning of a multi-trillion dollar mathematical mismatch, while finding selective value in PG&E and clinical biotech....
Risk Appetite
Risk appetite posture is low conviction: Greenlight Capital sits out the AI infrastructure boom, warning of a multi-trillion dollar mathematical mismatch, while finding selective value in PG&E and clinical biotech....
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Greenlight Capital sits out the AI infrastructure boom, warning of a multi-trillion dollar mathematical mismatch, while finding selective value in PG&E and clinical biotech....
Forward Guidance
Forward guidance signal: Greenlight Capital sits out the AI infrastructure boom, warning of a multi-trillion dollar mathematical mismatch, while finding selective value in PG&E and clinical biotech....
Language Signal
Tone analysis indicates high conviction language: Greenlight Capital sits out the AI infrastructure boom, warning of a multi-trillion dollar mathematical mismatch, while finding selective value in PG&E and clinical biotech....
Perceived Risk
Perceived risk level is evaluated as high conviction. Greenlight Capital sits out the AI infrastructure boom, warning of a multi-trillion dollar mathematical mismatch, while finding selective value in PG&E and clinical biotech....
Opportunity Density
Opportunity density index indicates moderate conviction actionable entry points. Greenlight Capital sits out the AI infrastructure boom, warning of a multi-trillion dollar mathematical mismatch, while finding selective value in PG&E and clinical biotech....
Time Horizon
Investment time horizon reflects a above average conviction orientation. Greenlight Capital sits out the AI infrastructure boom, warning of a multi-trillion dollar mathematical mismatch, while finding selective value in PG&E and clinical biotech....
